Edwards Lifesciences Corp (EW)

Operating profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	1,534,100	1,581,800	1,565,800	1,698,100	1,748,500	1,675,100	1,663,000	1,745,600	1,690,300	1,667,300	1,634,800	923,000	897,600	857,000	793,500	1,230,700	1,146,800	830,700	785,300	769,900
Revenue (ttm)	US$ in thousands	5,997,700	5,823,000	5,652,900	5,488,400	5,362,000	5,360,300	5,343,800	5,344,000	5,219,100	5,093,000	4,925,300	4,477,100	4,393,400	4,375,800	4,330,900	4,493,400	4,355,200	4,158,800	3,968,100	3,822,500
Operating profit margin		25.58%	27.16%	27.70%	30.94%	32.61%	31.25%	31.12%	32.66%	32.39%	32.74%	33.19%	20.62%	20.43%	19.58%	18.32%	27.39%	26.33%	19.97%	19.79%	20.14%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $1,534,100K ÷ $5,997,700K
= 25.58%

The operating profit margin of Edwards Lifesciences Corp has exhibited a declining trend over the last eight quarters, falling from 33.22% in Q4 2022 to 28.78% in Q4 2023. This suggests a gradual decrease in the efficiency of the company's operations in generating profits from its core business activities. Despite some fluctuations, the overall trajectory of the operating profit margin indicates a potential need for management to address factors impacting profitability and operational performance. Additional analysis and comparison with industry benchmarks may be useful in identifying areas for improvement and optimizing the company's financial performance.